A Study of PTX-9908 Injection for Non-resectable HCC with TACE

Launched by TCM BIOTECH INTERNATIONAL CORP. · Jan 17, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called PTX-9908 Injection for patients with a type of liver cancer known as non-resectable hepatocellular carcinoma (HCC) that cannot be surgically removed. The trial is divided into two phases. In the first phase, the researchers will test different doses of the injection to see which is the safest and most effective. Eligible participants must have recently completed a treatment called TACE (Transarterial Chemoembolization) and be recovering well. They should also be between 20 and 80 years old and have good liver and kidney function.

Participants in the trial will receive the PTX-9908 Injection for a total of four weeks, with daily doses during the first week and weekly doses for the following three weeks. After the treatment, there will be a follow-up period to monitor their health. This study is important because it aims to find a new option for patients with HCC who have limited treatment choices. If you or a loved one is considering participating, it's essential to discuss it with a healthcare provider to understand the potential benefits and risks.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Unresectable hepatocellular carcinoma and at intermediate-stage HCC (BCLC stage B or Child-Pugh class A/B with large or multifocal HCC, no vascular invasion, or extrahepatic spread) with completed TACE procedure in 4 weeks before day 1 of study intervention infusion.
• • 2. Recovered from TACE treatment and procedure related toxicities including ALT/AST and bilirubin within normal limit or reference numeric value (reference value is defined as the test value before TACE procedure).
• • 3. ECOG (Eastern Cooperative Oncology Group) performance status \< 2.
• 4. Have adequate organ and marrow function as defined below:
• • 1. Absolute neutrophil count \> 1,200/µL
• • 2. Hemoglobin \> 9 g/dL
• • 3. Platelets \> 100,000/µL
• • 4. Total bilirubin \< 2 X ULN
• • 5. Have adequate kidney function as estimated glomerular filtration rate (eGFR) \> 60 mL/min/1.73m2
• • 6. A negative pregnancy test at screening. This applies to any female patient with childbearing potential.
• • 7. Agree to use adequate contraception after signing informed consent form, during the duration of study participation and for at least 4-weeks after completion or withdrawal from the study. This applies to any female patient with childbearing potential and any male patient whose female partner has childbearing potential.
• Acceptable contraceptive methods include:
• • 1. Established use of oral, injected or implanted hormonal methods of contraception
• • 2. Placement of an intrauterine device (IUD) or intrauterine system (IUS)
• • 3. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) \>=20 years of age. (Note: In Taiwan, age of majority recognized in law is 20 years of age)
• • 8. \>=20 years of age. (Note: In Taiwan, age of majority recognized in law is 20 years of age)
• • 9. Anticipated life expectancy of \>= 6 months at assessment during screening.
• • 10. Ability to understand and have signed a written informed consent document.
• Exclusion Criteria:
• • 1. 1. Patient with Child-Pugh B8-9.
• • 2. Patient who has had anti-cancer therapy including surgery, radiotherapy, immunotherapy, or chemotherapy (except in TACE regimen) within 4 weeks prior to the screening visit.
• • 3. Patient who has received any other investigational agents within 4 weeks prior to the screening visit.
• • 4. Patient who has not recovered from the side effects of the earlier investigational agent or had anti-cancer therapy including surgery, radiotherapy, immunotherapy, or chemotherapy.
• • 5. Patient with known brain metastases, leptomeningeal or epidural metastases (unless treated and well controlled for \>= 3 months).
• • 6. Patient with prior history of co-malignancies, except for adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ (DCIS) of the breast, and basal cell/squamous cell skin cancer.
• • 7. Patient with history of myocardial infarction or uncontrolled cardiac dysfunction, or unstable arrhythmia or symptomatic peripheral arterial vascular disease.
• • 8. Patient with history of positive serology for human immunodeficiency virus (HIV).
• • 9. Patient with active, uncontrolled bacterial, viral, or fungal infections, which require systemic therapy.
• • 10. Patient with poor liver function as indicated by serum bilirubin \> 2 mg/dL, Child-Pugh Class C, severe coagulopathy (INR \> 2) not correctable with vitamin K, or active hepatic encephalopathy.
• • 11. Patient with known allergic reactions to biological agent or polypeptides similar to PTX-9908 Injection.
• • 12. Woman who is pregnant or nursing.
• • 13. Patient with concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the patient in this study.
• • 14. Patient with unwillingness or inability to comply with the study protocol for any reason.
• • 15. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \>480 milliseconds (ms) (CTCAE grade 1) using Frederica's QT correction formula
• • 16. A history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
• • 17. The use of concomitant medications that prolong the QT/QTc interval